scholarly article | Q13442814 |
P50 | author | Yoshinori Kato | Q44454669 |
Phuoc T. Tran | Q55459004 | ||
Kekoa Taparra | Q57618681 | ||
Michael Lim | Q87792919 | ||
Hailun Wang | Q89307804 | ||
P2093 | author name string | Joseph M Herman | |
Jessica A Cades | |||
Robert A Anders | |||
David Proia | |||
Anvesh Annadanam | |||
Katriana M Nugent | |||
Matthew Ballew | |||
Reem Malek | |||
Sarah Manmiller | |||
Sivarajan T Chettiar | |||
Zineb Belcaid | |||
P2860 | cites work | Pathogenesis of hepatocellular carcinoma and molecular therapies. | Q37456002 |
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. | Q37820497 | ||
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation | Q38247880 | ||
Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma | Q39185396 | ||
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. | Q39203018 | ||
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy | Q39432501 | ||
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation | Q40600964 | ||
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization | Q40632085 | ||
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. | Q44705946 | ||
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer | Q46518366 | ||
Mean inactivation dose: a useful concept for intercomparison of human cell survival curves | Q71405944 | ||
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma | Q85364824 | ||
How grim is hepatocellular carcinoma? | Q27001669 | ||
Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition | Q28301955 | ||
The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product | Q28316871 | ||
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling | Q28741023 | ||
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
Survival and death signals can predict tumor response to therapy after oncogene inactivation | Q30574736 | ||
Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer | Q33836330 | ||
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer | Q33912171 | ||
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities | Q34646117 | ||
Inhibition of HSP90 molecular chaperones: moving into the clinic | Q34654791 | ||
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma | Q34770140 | ||
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. | Q35360310 | ||
Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma | Q35550129 | ||
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells | Q35818450 | ||
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. | Q36336795 | ||
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer | Q36347106 | ||
Genetics of hepatocellular tumors. | Q36519006 | ||
Sorafenib for treatment of hepatocellular carcinoma: a systematic review | Q36680204 | ||
Genomics and signaling pathways in hepatocellular carcinoma. | Q36733952 | ||
High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities | Q37020792 | ||
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. | Q37157400 | ||
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair | Q37163368 | ||
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer | Q37235527 | ||
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer | Q37417712 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 4 | |
P921 | main subject | liver cancer | Q623031 |
P304 | page(s) | 457-466 | |
P577 | publication date | 2016-03-16 | |
P1433 | published in | Cancer Biology and Therapy | Q2544651 |
P1476 | title | Ganetespib radiosensitization for liver cancer therapy | |
P478 | volume | 17 |
Q47102428 | Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition |
Q64266721 | Evaluation of the Radiosensitizing Potency of Bromelain for Radiation Therapy of 4T1 Breast Cancer Cells |
Q42364239 | The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks |
Search more.